Will enGene Therapeutics report positive interim data for DETAIL trial by Q1 2027?
sec_filing· product
Will enGene Therapeutics report positive interim data for DETAIL tria…
Market overview
The company guided for interim efficacy data in Q1 2027. Given typical biotech success rates (~30-40% for Phase 2/3 in oncology), we assign a 35% probability of positive data.
product prediction market
- Implied probability (Yes)
- 35%
- Closes
- 2027-03-31
Source: sec_filing
More product markets
- Will Ocado partnership meet 35% productivity target? — 70% Yes
- Will DCI announce new EV contract worth >$50M? — 55% Yes
- Will the company announce a renewable energy contract by 2026-12-31? — 65% Yes
- Will Phase 2 enrollment reach 50/60 patients by 2026-12-31? — 90% Yes
- Will ServiceTitan announce a major AI partnership or acquisition by end of 2026? — 30% Yes
- Will fintech firms offering real-time fund verification see increased demand? — 75% Yes
- Will Bamboo Insurance announce a reduction in CAC by at least 15% within 90 days of the S-1 filing? — 35% Yes
- Will private label exceed 33% penetration by EOY? — 60% Yes
No one's made a Conviction call on this yet. Be the first to call it →
Loading…